Inferra AI / Company / NVS
Novartis
NVS · Health Care
Last earnings Oct 27, 2026
Key results
Net incomequarter
71%
net income down -71% (cc, -70% USD) Q3 core EPS 1 grew +8% (cc, +9% USD) to USD 2.46 Q3 free cash flow 1 was USD 5.1 billion (-18% USD) 9 months net sales (0% cc, +2% USD) and core operating income (-2% cc
SEC original ↗Novartis — Earnings release (6-K exhibit)EX-99Oct 27, 2026
EPSquarter
70%
net income down -71% (cc, -70% USD) Q3 core EPS 1 grew +8% (cc, +9% USD) to USD 2.46 Q3 free cash flow 1 was USD 5.1 billion (-18% USD) 9 months net sales (0% cc, +2% USD) and core operating income (-2% cc
SEC original ↗Novartis — Earnings release (6-K exhibit)EX-99Oct 27, 2026
Free cash flowquarter
9%
net income down -71% (cc, -70% USD) Q3 core EPS 1 grew +8% (cc, +9% USD) to USD 2.46 Q3 free cash flow 1 was USD 5.1 billion (-18% USD) 9 months net sales (0% cc, +2% USD) and core operating income (-2% cc
SEC original ↗Novartis — Earnings release (6-K exhibit)EX-99Oct 27, 2026
Revenuequarter
0%
net income down -71% (cc, -70% USD) Q3 core EPS 1 grew +8% (cc, +9% USD) to USD 2.46 Q3 free cash flow 1 was USD 5.1 billion (-18% USD) 9 months net sales (0% cc, +2% USD) and core operating income (-2% cc
SEC original ↗Novartis — Earnings release (6-K exhibit)EX-99Oct 27, 2026
Operating incomequarter
59%
Operating income was USD 1.8 billion (-59%, -61% cc), declining mainly due to higher R&D expenses, including a USD 1.9 billion partial impairment charge of the del-desiran IPR&D asset, and higher other expense, partly offset by higher net sales.
SEC original ↗Novartis — Earnings release (6-K exhibit)EX-99Oct 27, 2026
Net income was USD 1.2 billion (-70%, -71% cc), declining mainly due to lower operating income and higher interest expense.
SEC original ↗Novartis — Earnings release (6-K exhibit)EX-99Oct 27, 2026
Core operating incomequarter
11%
Core operating income was USD 6.0 billion (+11%, +10% cc), mainly driven by higher net sales.
SEC original ↗Novartis — Earnings release (6-K exhibit)EX-99Oct 27, 2026
Core net incomequarter
8%
Core net income was USD 4.7 billion (+8%, +6% cc), driven by higher core operating income, partly offset by higher interest expense.
SEC original ↗Novartis — Earnings release (6-K exhibit)EX-99Oct 27, 2026
Free cash flow amounted to USD 5.1 billion (-18%), declining due to lower net cash flows from operating activities.
SEC original ↗Novartis — Earnings release (6-K exhibit)EX-99Oct 27, 2026
Operating income was USD 10.8 billion (-23%, -24% cc), declining mainly due to higher R&D expenses, including a USD 1.9 billion partial impairment charge of the del-desiran IPR&D asset, and higher other expense.
SEC original ↗Novartis — Earnings release (6-K exhibit)EX-99Oct 27, 2026
2 Net income was USD 7.6 billion (-34%, -35% cc), mainly due to lower operating income, higher interest expense and higher income taxes.
SEC original ↗Novartis — Earnings release (6-K exhibit)EX-99Oct 27, 2026
AI analysis
Latest earnings event · reported Oct 27, 2026
Based on: Earnings release (6-K exhibit) + parent 6-K — transcript not held
Headline figures
| Metric | Latest earnings event | Prior qtr | Year ago |
|---|---|---|---|
| Net income | 71% | 19% | — |
| EPS | 70% | 1% | — |
| Free cash flow | 9% | 0% | — |
| Revenue | 0% | 2% | — |
| Operating income | 59% | 1% | — |
| Core operating income | 11% | 0% | — |
| Core net income | 8% | 3% | — |
Guidance · company-stated
No guidance located in the held release
“com/novartisnews FINANCIAL RESULTS | FINANZERGEBNISSE Novartis delivered sales growth and core margin expansion in Q3; raised FY core operating income guidance Ad hoc announcement pursuant to Art.”
Cash flow & capex
Capital allocation
During the first nine months of 2026, Novartis repurchased 30.9 million shares for USD 4.7 billion on the SIX Swiss Exchange second trading line.
These repurchases included 18.8 million shares (USD 2.8 billion) under the up-to USD 10 billion share buyback announced in July 2025 (with up to USD 4.9 billion still to be executed).
Event summary
At the same time, we continued to advance our pipeline, with positive Phase III results for remibrutinib in RMS, label expansions for Rhapsido and Pluvicto in the US, and the first submission for pelabresib in the EU
Based on: Earnings release (6-K exhibit) + parent 6-K — transcript not held
Guidance & outlook
No guidance located in the held release
Capital allocation
During the first nine months of 2026, Novartis repurchased 30.9 million shares for USD 4.7 billion on the SIX Swiss Exchange second trading line.
SEC original ↗Novartis — Earnings release (6-K exhibit)EX-99Oct 27, 2026
These repurchases included 18.8 million shares (USD 2.8 billion) under the up-to USD 10 billion share buyback announced in July 2025 (with up to USD 4.9 billion still to be executed).
SEC original ↗Novartis — Earnings release (6-K exhibit)EX-99Oct 27, 2026
In addition, 12.1 million shares (USD 1.8 billion) were repurchased to mitigate the anticipated full-year dilution related to participation plans of employees.
SEC original ↗Novartis — Earnings release (6-K exhibit)EX-99Oct 27, 2026
Further, 2.0 million shares (USD 0.3 billion) were repurchased from employees.
SEC original ↗Novartis — Earnings release (6-K exhibit)EX-99Oct 27, 2026
The increase was mainly due to the free cash flow of USD 14.0 billion being more than offset by the net cash outflow for M&A, intangible assets transactions and other acquisitions of USD 16.7 billion, the USD 9.1 billion annual dividend payment and cash outflows for treasury share transactions of USD 4.8 billion.
SEC original ↗Novartis — Earnings release (6-K exhibit)EX-99Oct 27, 2026
Capital structure and net debt Retaining a good balance between investment in the business, a strong capital structure, and attractive shareholder returns remains a priority.
SEC original ↗Novartis — Earnings release (6-K exhibit)EX-99Oct 27, 2026
Strategy & priorities
com/novartisnews FINANCIAL RESULTS | FINANZERGEBNISSE Novartis delivered sales growth and core margin expansion in Q3; raised FY core operating income guidance Ad hoc announcement pursuant to Art.
SEC original ↗Novartis — Earnings release (6-K exhibit)EX-99Oct 27, 2026
Strategy Our focus Novartis is a “pure-play” innovative medicines company.
SEC original ↗Novartis — Earnings release (6-K exhibit)EX-99Oct 27, 2026
We have a clear focus on four core therapeutic areas (cardiovascular-renal-metabolic, immunology, neuroscience and oncology), with multiple significant in-market and pipeline assets in each of these areas, that address high disease burden and have substantial growth potential.
SEC original ↗Novartis — Earnings release (6-K exhibit)EX-99Oct 27, 2026
In addition to two established technology platforms (chemistry and biotherapeutics), three emerging platforms (gene & cell therapy, radioligand therapy and xRNA) are being prioritized for continued investment into new R&D capabilities and manufacturing scale.
SEC original ↗Novartis — Earnings release (6-K exhibit)EX-99Oct 27, 2026
Geographically, we are focused on growing in our priority geographies – the US, China, Germany and Japan.
SEC original ↗Novartis — Earnings release (6-K exhibit)EX-99Oct 27, 2026
Risks & headwinds
Such forward-looking statements are based on the current beliefs and expectations of management regarding future events and are subject to significant known and unknown risks and uncertainties.
SEC original ↗Novartis — Earnings release (6-K exhibit)EX-99Oct 27, 2026
Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements.
SEC original ↗Novartis — Earnings release (6-K exhibit)EX-99Oct 27, 2026
Novartis is in US ANDA litigation with a generic manufacturer.
SEC original ↗Novartis — Earnings release (6-K exhibit)EX-99Oct 27, 2026
Novartis is in patent litigation with two manufacturers having FDA applications referencing Lutathera, which have received final approval in the US.
SEC original ↗Novartis — Earnings release (6-K exhibit)EX-99Oct 27, 2026
Any commercial launch of a product referencing Lutathera prior to the final outcome of the appeal may be at risk of later litigation developments.
SEC original ↗Novartis — Earnings release (6-K exhibit)EX-99Oct 27, 2026
What changed vs prior quarter
Net income — prior quarter passage and this quarter's passage are both cited.
SEC original ↗Novartis — Earnings release (6-K exhibit)EX-99Oct 27, 2026
Operating income — prior quarter passage and this quarter's passage are both cited.
SEC original ↗Novartis — Earnings release (6-K exhibit)EX-99Oct 27, 2026
Core operating income — prior quarter passage and this quarter's passage are both cited.
SEC original ↗Novartis — Earnings release (6-K exhibit)EX-99Oct 27, 2026
Earnings deck slides
1 deck with slide viewCompetitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
61 documents- Q3 2026
- 6-KNVS
Oct 27, 2026
- Q2 2026
- 6-KNVS
Sep 8, 2026
- 6-KNVS
Sep 4, 2026
- 6-KNVS
Sep 1, 2026
- 6-KNVS
Jul 21, 2026
- Q1 2026
- 6-KNVS
Jun 11, 2026
- 6-KNVS
Apr 28, 2026
- Q4 2025
- 6-KNVS
Mar 18, 2026
- EX-99NVS
Mar 18, 2026
- 6-KNVS
Feb 4, 2026
- 6-KNVS
Feb 4, 2026
- 20-FNVS
Feb 4, 2026
- Q3 2025
- 6-KNVS
Nov 25, 2025
- 6-KNVS
Nov 20, 2025
- 6-KNVS
Nov 5, 2025
- 6-KNVS
Oct 28, 2025
- 6-KNVS
Oct 27, 2025
- Q2 2025
- 6-KNVS
Sep 30, 2025
- 6-KNVS
Aug 11, 2025
- 6-KNVS
Jul 17, 2025
- 6-KNVS
Jul 17, 2025
- Q1 2025
- 6-KNVS
Jun 2, 2025
- 6-KNVS
Apr 29, 2025
- 6-KNVS
Apr 3, 2025
- Q4 2024
- 6-KNVS
Mar 28, 2025
- 6-KNVS
Jan 31, 2025
- 6-KNVS
Jan 31, 2025
- 20-FNVS
Jan 31, 2025
- Q3 2024
- 6-KNVS
Dec 30, 2024
- 6-KNVS
Nov 25, 2024
- 6-KNVS
Oct 29, 2024
- 6-KNVS
Oct 29, 2024
- Q2 2024
- 6-KNVS
Sep 18, 2024
- 6-KNVS
Sep 17, 2024
- 6-KNVS
Aug 8, 2024
- 6-KNVS
Jul 18, 2024
- Q1 2024
- 6-KNVS
Apr 23, 2024
- Q4 2023
- 20-FNVS
Jan 31, 2024
- 6-KNVS
Jan 31, 2024
- 6-KNVS
Jan 31, 2024
- 6-KNVS
Jan 8, 2024
- Q3 2023
- 6-KNVS
Dec 11, 2023
- 6-KNVS
Dec 6, 2023
- 6-KNVS
Nov 28, 2023
- 6-KNVS
Oct 30, 2023
- 6-KNVS
Oct 24, 2023
- 6-KNVS
Oct 4, 2023
- 6-KNVS
Oct 2, 2023
- Q2 2023
- 6-KNVS
Sep 5, 2023
- 6-KNVS
Aug 21, 2023
- 6-KNVS
Aug 9, 2023
- 6-KNVS
Jul 18, 2023
- 6-KNVS
Jul 10, 2023
- Q1 2023
- 6-KNVS
Jun 12, 2023
- 6-KNVS
Apr 25, 2023
- Q4 2022
- 6-KNVS
Mar 27, 2023
- 20-FNVS
Feb 1, 2023
- 6-KNVS
Feb 1, 2023
- 6-KNVS
Feb 1, 2023
- Q3 2022
- 6-KNVS
Dec 5, 2022
- 6-KNVS
Oct 25, 2022
Earnings releases
6 documentsPresentations
1 document- Other presentations
- NVSDeck
Transcripts
0 documentsNo transcripts for Novartis are held in this edition of the library.
Mentioned by
25 companiesOther tracked companies whose held documents mention Novartis by name or ticker. A mention is counted once per document, from the document text the library holds.
Alnylam Pharmaceuticals (ALNY)
“ of $1,646 Million for ONPATTRO… …commercialization of certain products, including Roche, Novartis, Sanofi, Regeneron and Vir; the outcome of litigation; the risk of future government investigations; and unexpected expenditures; as well as those risk”
“quarter of 2025. For the year ended December… …dispute settlement In May 2025, Incyte and Novartis entered into a settlement agreement with respect to litigation relating to the duration of royalty payments owed under the Collaboration and License Ag”
“entation. (4) Exclusivity protection provided by Genmab patents (exp. 2031) and Novartis owned patents (exp. 2037). Royalties continue to be paid on all sales after… …interested in developing potential antibody therapeutics using our techno”
Harmony Gold Mining Co Ltd (HMY)
“ of $1,646 Million for ONPATTRO… …commercialization of certain products, including Roche, Novartis, Sanofi, Regeneron and Vir; the outcome of litigation; the risk of future government investigations; and unexpected expenditures; as well as those risk”
“ public, and as General Counsel of Endocyte, Inc. through its $2.1 billion acquisition by Novartis AG leading to the successful launch of Pluvicto®. Earlier, Mr. McAvoy spent 27 years at… …a20260831-8xkxpressrelea Vaxcyte Appoints Chief M”
“…through the date hereof, as the MDCO License Agreement. In 2020, Novartis AG, or Novartis, completed its acquisition of MDCO and assumed all of MDCO’s rights and obligations under the MDCO License Agreement. We are entitled… ”
“…through the date hereof, as the MDCO License Agreement. In 2020, Novartis AG, or Novartis, completed its acquisition of MDCO and assumed all of MDCO’s rights and obligations under the MDCO License Agreement. As of September… ”
“ of patisiran for the treatment… …commercialization of certain products, including Roche, Novartis, Sanofi, Regeneron and Vir; the outcome of litigation; the risk of future government investigations; and unexpected expenditures; as well as those risk”
“…commercialization of certain products, including Roche, Novartis, Sanofi, and Regeneron; the outcome of litigation; the risk of future government investigations; and unexpected expenditures; as well as those risks …”
“he quarter was more than double… …commercialization of certain products, including Roche, Novartis, Sanofi, and Regeneron; the outcome of litigation and government investigations; the risk of future litigation and government investigations; and unexp”
“ of ONPATTRO for the treatment … …commercialization of certain products, including Roche, Novartis, Sanofi, Regeneron and Vir; the outcome of litigation; the risk of future government investigations; and unexpected expenditures; as well as those risk”
“rter of 2026. • Opzelura net sales increased… …dispute settlement In May 2025, Incyte and Novartis entered into a settlement agreement with respect to litigation relating to the duration of royalty payments owed under the Collaboration and License Ag”
“nologies for civilian use are regulated under the PRC Administrative Regulations… …former Novartis tislelizumab and ociperlimab collaborations which were terminated in the prior year. Gross Margin Gross margin on global product sales increased to $3.”
“eveloping a new class of antibody-drug conjugates (ADCs). The acquisition strengthens the Novartis oncology pipeline with two lead ADC assets targeting B7-H3 and HER2 and a… …from our external business opportunities; the development or adoption of n”
“7 -18 3.37 3.91 -14 -15 Net cash flows from operating activities… …bank to repurchase Novartis shares on the second trading line under its up-to USD 15.0 billion share buyback. In June 2024, Novartis amended the arrangement to include the repurch”
“6,964 Total current assets … …commercialization of certain products, including Roche, Novartis, Sanofi, and Regeneron; the outcome of litigation; the risk of future government investigations; and unexpected expenditures; as well as those risks … ”
“1,892 Total current assets … …commercialization of certain products, including Roche, Novartis, Sanofi, and Regeneron; the outcome of litigation and government investigations; the risk of future litigation and government investigations; and unexp”
Fidelity National Information Services (FIS)
“SD m 3… …intellectual property protection, including the ultimate extent of the impact on Novartis of the loss of patent protection and exclusivity on key products; our ability to realize the strategic benefits, operational… … to equity-based compens”
“ 1.65 1.83 -10 -11 Net … …bank to repurchase Novartis shares on the second trading line under its up-to USD 15.0 billion share buyback. In June 2024, Novartis amended the arrangement to include the repur”
“6,964 Total current assets … …commercialization of certain products, including Roche, Novartis, Sanofi, and Regeneron; the outcome of litigation and government investigations; the risk of future litigation and government investigations; and unexp”
“loss) per share $ (0.21 ) $ 0.19 $ 0.57 $ … …Novartis collaboration. The weighted-average shares outstanding used to compute diluted earnings per share was 42,388,867 for the year ended De”
“/(loss) margins and core operating income margins are calculated based upon net sales… …("Novartis" or "Former Parent"), lower separation and transformation costs, partially offset by a $49 million impairment of an intangible asset, increased investm”
“erating … …included the recognition of $5.7 million from the company’s collaboration with Novartis. • Software gross margin was 72% for the first quarter, compared to 76% in the first quarter of 2024, primarily reflecting the… …$48.8 Million Initial ”
Monte Rosa Therapeutics, Inc. (GLUE)
“(0.29 ) $ (0.70 ) $ (1.21 ) $ (2.06 ) Weighted-average… …Novartis, the Company expects its cash and cash equivalents to be sufficient to fund planned operations and capital expenditures into 2028. About MRT-2359 ”
Janux Therapeutics, Inc. (JANX)
“ny through multiple strategic growth initiatives ultimately leading to its acquisition by Novartis in 2023 for $3.5 billion. Prior to Chinook, Mr. Dobmeier spent 16 years in a series of … … ) $ (17,829 ) $ (23,000 ) $ (34,492 ”
See also the earnings calendar for every tracked company’s next earnings date.